



# Louisiana

## **Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions**

**Policy #** 00091

**Original Effective Date:** 08/26/2002

**Current Effective Date:** 05/01/2021

*Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.*

*Note: Autologous Chondrocyte Implantation for Focal Articular Cartilage Lesions is addressed in medical policy number 00006.*

*Note: Meniscal Allografts and Other Meniscal Implants are addressed in medical policy number 00083.*

### **When Services May Be Eligible for Coverage**

*Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:*

- *Benefits are available in the member's contract/certificate, and*
- *Medical necessity criteria and guidelines are met.*

#### **Autograft or Autologous Mosaicplasty - Knee**

Based on review of available data, the Company may consider osteochondral autografts/mosaicplasty and osteochondral allografts in the treatment of focal articular cartilage lesions to be **eligible for coverage\*\*** when patient selection criteria are met.

#### **Patient Selection Criteria**

Coverage eligibility will be considered when ALL of the criteria listed below are met and no exclusion criteria are present (see exclusion criteria below):

- Size of cartilage defect is between 1.0 to 2.5 cm<sup>2</sup> total area, as documented by magnetic resonance imaging (MRI) or arthroscopy; AND
- Symptomatic, focal, full thickness (grade III or IV) isolated defect of the knee involving the weight bearing surface of the medial or lateral femoral condyles, trochlear or patellar region caused by acute or repetitive trauma; AND
- Age 15-55 years. Adolescent patients should be skeletally mature with documented closure of growth plates. Adult patients should be too young to be considered an appropriate

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

candidate for total knee arthroplasty or other reconstructive surgery, or when > 55 years of age must not have arthritis present on x-ray; AND

- Persistent symptoms of disabling localized knee pain for at least three (3) months, which has failed to respond to conservative treatment tried for a minimum of 6 weeks (See Policy Guidelines); AND
- Discrete lesion, single and unipolar (involving only one side of the joint – "kissing lesions" are not eligible for coverage), largely contained with near normal surrounding articular cartilage and articulating cartilage, (Outerbridge grades 0, 1, 2); AND
- Normal joint space present without evidence of inflammation or degenerative changes, and normal knee biomechanics, or alignment and stability achieved concurrently with osteochondral grafting; AND
- Patient is willing and able to comply with post-operative weight-bearing restrictions and rehabilitation.

### Autograft - Talus

Based on review of available data, the Company may consider osteochondral autografting, using one or more cores of osteochondral tissue to be **eligible for coverage\*\*** when patient selection criteria are met.

#### Patient Selection Criteria

Coverage eligibility for osteochondral autografting, using one or more cores of osteochondral tissue may be considered when EITHER of the criteria listed below are met:

- Large (area >1.5 cm<sup>2</sup>) or cystic (volume >3.0 cm<sup>3</sup>) osteochondral lesions of the talus; OR
- Revision surgery after failed marrow stimulation for osteochondral lesion of the talus.

### Allograft – Knee

Based on review of available data, the Company may consider osteochondral allograft of the knee to be **eligible for coverage\*\*** when patient selection criteria are met.

#### Patient Selection Criteria

Coverage eligibility for osteochondral allograft of the knee will be considered when ALL of the criteria listed below are met and no exclusion criteria are present (see exclusion criteria below):

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

- Size of the cartilage defect is greater than or equal to 2 cm<sup>2</sup> total area, as documented by MRI or arthroscopy; AND
- Focal, full thickness, (grade III or IV) isolated defect of the knee involving the weight bearing surface of the medial or lateral femoral condyles or trochlear region caused by acute or repetitive trauma; AND
- Skeletal maturity as documented by closure of growth plates; and
- Persistent symptoms of disabling localized knee pain for at least three (3) months, which has failed to respond to conservative treatment tried for a minimum of 6 weeks (See Policy Guidelines); AND
- When other cartilage repair techniques (e.g. microfracture, osteochondral autografting or autologous chondrocyte implantation [ACI]) would be inadequate due to lesion size, location, or depth; AND
- The knee is stable, with functionally intact menisci and ligaments and normal alignment; and
- Discrete lesion, single and unipolar (involving only one side of the joint - "kissing lesions" are not eligible for coverage), largely contained with near normal surrounding articular cartilage and articulating cartilage, (grades 0, 1, 2); AND
- Normal joint space present, without evidence of inflammation or degenerative changes ; and
- Patient is willing and able to comply with post-operative weight-bearing restrictions and rehabilitation.

Note: Corrective procedures, e.g., ligament or tendon repair, osteotomy for alignment, meniscal allograft transplant or repair, may be performed in combination with, or prior to, osteochondral transplantation.

### **Allograft - Talus**

Based on review of available data, the Company may consider osteochondral fresh allografting as a repair technique to be **eligible for coverage\*\*** when patient selection criteria are met.

### **Patient Selection Criteria**

Coverage eligibility may be considered for osteochondral fresh allografting as a repair technique when EITHER of the criteria listed below are met:

- Large (area >1.5 cm<sup>2</sup>) or cystic (volume >3.0 cm<sup>3</sup>) osteochondral lesions of the talus when autografting would be inadequate due to lesion size, depth, or location; OR

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

- Revision surgery after failed prior marrow stimulation for large (area  $>1.5 \text{ cm}^2$ ) or cystic (volume  $>3.0 \text{ cm}^3$ ) osteochondral lesions of the talus when autografting would be inadequate due to lesion size, depth or location.

### **Exclusion Criteria for Autograft and Allograft of the Knee**

Coverage is not available for patients when ANY of the criteria listed below are present:

- Localized or systemic infection; OR
- Uncorrected maltracking/malalignment of the knee; OR
- Unstable knee and corrective procedure is not planned; OR
- History of malignancy in bones, cartilage, fat or muscle in the treated leg; OR
- Body Mass Index (BMI) of greater than 35.

### **When Services Are Considered Investigational**

*Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.*

The use of osteochondral autografts/mosaicplasty and osteochondral allografts in the treatment of focal articular cartilage lesions when patient selection criteria are not met is considered **investigational**.\*

Based on review of available data, the Company considers the use of osteochondral autograft/mosaicplasty and osteochondral allograft transplantation for joints other than those listed above, to be **investigational**.\*

Based on review of available data, the Company considers the treatment of focal articular cartilage lesions with autologous or allogeneic minced or particulated cartilage to be **investigational**.\*

Based on review of available data, the Company considers treatment of focal articular cartilage lesions with decellularized osteochondral allograft plugs (e.g., Chondrofix) to be **investigational**.\*

Based on review of available data, the Company considers treatment of focal articular cartilage lesions with reduced osteochondral allograft discs (e.g., ProChondrix, Cartiform) to be **investigational**.\*

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

### **Policy Guidelines**

**Conservative management** offered by the provider or other health professionals for this condition(s) should include a combination of strategies to reduce inflammation, alleviate pain, and improve function, including requirements for physical therapy AND at least one complementary conservative management strategy.

Physical therapy requirement at least ONE of the following:

- Physical therapy; OR
- Physician or physical therapist-supervised therapeutic home exercise program which includes flexibility and muscle strengthening exercises; OR
- Exception to the physical therapy requirement in unusual circumstances (for instance intractable pain so severe that physical therapy is not possible) when clearly documented in the medical record.

Complementary conservative management requirement at least ONE of the following:

- Activity modification; OR
- Prescription strength anti-inflammatory medications and analgesics; OR
- Intraarticular corticosteroid injection(s).

Documentation of compliance with a plan of therapy that includes elements from these areas is required where conservative management is appropriate.

### **Background/Overview**

#### **Articular Cartilage Lesions**

Damaged articular cartilage can be associated with pain, loss of function, and disability, and can lead to debilitating osteoarthritis over time. These manifestations can severely impair an individual's activities of daily living and quality of life. The vast majority of osteochondral lesions occur in the knee with the talar dome and capitulum being the next most frequent sites. The most common locations of lesions are the medial femoral condyle (69%), followed by the weight-bearing portion of the lateral femoral condyle (15%), the patella (5%), and trochlear fossa. Talar lesions are reported to be about 4% of osteochondral lesions.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

### **Treatment**

There are two main goals of conventional therapy for patients who have significant focal defects of the articular cartilage: symptom relief and articular surface restoration.

First, there are procedures intended primarily to achieve symptomatic relief: débridement (removal of debris and diseased cartilage) and rehabilitation. Second, there are procedures intended to restore the articular surface. Treatments may be targeted to the focal cartilage lesion, and most such treatments induce local bleeding, fibrin clot formation, and resultant fibrocartilage growth. These marrow stimulation procedures include microfracture, abrasion arthroplasty, and drilling, all of which are considered standard therapies.

### **Microfracture**

Microfracture is an arthroscopic procedure in which a small pick creates a network of holes at the base of the articular cartilage lesion, allowing blood into the injured area to form clots and subsequent fibrocartilage growth. Efficacy of the microfracture technique for articular cartilage lesions of the knee was examined by Mithoefer et al (2009) in a systematic review. Twenty-eight studies (total n=3122 patients) were selected; 6 studies were randomized controlled trials. Microfracture was found to improve knee function in all studies during the first 24 months after the procedure but the reports on durability were conflicting. A prospective longitudinal study of 110 patients by Solheim et al (2016) found that, at a mean of 12 years (range, 10-14 years) after microfracture, 45.5% of patients had poor outcomes, including 43 patients who required additional surgery. The size of the lesion has also been shown to affect outcomes following marrow stimulation procedures.

### **Abrasion and Drilling**

Abrasion and drilling are techniques to remove damaged cartilage. Instead of a drill, high speed burrs are used in the abrasion procedure.

Fibrocartilage is generally considered to be less durable and mechanically inferior to the original articular cartilage. Thus, various strategies for chondral resurfacing with hyaline cartilage have been investigated. Alternatively, treatments of very extensive and severe cartilage defects may resort to complete replacement of the articular surface either by osteochondral allotransplant or artificial knee replacement.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.





# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

### **Osteochondral Grafting**

Autologous or allogeneic grafts of osteochondral or chondral tissue have been proposed as treatment alternatives for patients who have clinically significant, symptomatic, focal defects of the articular cartilage. It is hypothesized that the implanted graft's chondrocytes retain features of hyaline cartilage that is similar in composition and property to the original articulating surface of the joint. If true, the restoration of a hyaline cartilage surface might restore the integrity of the joint surface and promote long-term tissue repair, thereby improving function and delaying or preventing further deterioration.

Both fresh and cryopreserved allogeneic osteochondral grafts have been used with some success. However, cryopreservation decreases the viability of cartilage cells and fresh allografts may be difficult to obtain and create concerns regarding infectious diseases. As a result, autologous osteochondral grafts have been investigated as an option to increase the survival rate of the grafted cartilage and to eliminate the risk of disease transmission. Autologous grafts are limited by the small number of donor sites; thus, allografts are typically used for larger lesions. In an effort to extend the amount of the available donor tissue, investigators have used multiple, small osteochondral cores harvested from non-weight-bearing sites in the knee for treatment of full-thickness chondral defects. Several systems are available for performing this procedure: the Mosaicplasty System (Smith & Nephew), the OATS (Osteochondral Autograft Transfer System; Arthrex), and the COR and COR2 systems (DePuy Mitek). Although mosaicplasty and autologous osteochondral transplantation (AOT) may use different instrumentation, the underlying mode of repair is similar (ie, use of multiple osteochondral cores harvested from a non-weight-bearing region of the femoral condyle and autografted into the chondral defect). These terms have been used interchangeably to describe the procedure.

Preparation of the chondral lesion involves débridement and preparation of recipient tunnels. Multiple individual osteochondral cores are harvested from the donor site, typically from a peripheral non-weight-bearing area of the femoral condyle. Donor plugs range from 6 to 10 mm in diameter. The grafts are press fit into the lesion in a mosaic-like fashion into the same-sized tunnels. The resultant surface consists of transplanted hyaline articular cartilage and fibrocartilage, which is thought to provide "grouting" between the individual autografts. Mosaicplasty or AOT may be performed with either an open approach or arthroscopically. Osteochondral autografting has also been investigated as a treatment of unstable osteochondritis dissecans lesions using multiple dowel grafts to secure the fragment. While osteochondral autografting is primarily performed on the

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

femoral condyles of the knee, osteochondral grafts have been used to repair chondral defects of the patella, tibia, and ankle. With osteochondral autografting, the harvesting and transplantation can be performed during the same surgical procedure. Technical limitations of osteochondral autografting are difficulty in restoring concave or convex articular surfaces, the incongruity of articular surfaces that can alter joint contact pressures, short-term fixation strength and load-bearing capacity, donor-site morbidity, and lack of peripheral integration with peripheral chondrocyte death.

Reddy et al (2007) evaluated donor-site morbidity in 11 of 15 patients who had undergone graft harvest from the knee (mean, 2.9 plugs) for treatment of osteochondral lesions of the talus. At an average 47-month follow-up (range, 7-77 months), 5 patients were rated as having an excellent Lysholm Knee Scale score (95-100 points), 2 as good (84-94 points), and 4 as poor ( $\leq 64$  points). The reported knee problems were instability in daily activities, pain after walking one mile or more, slight limp, and difficulty squatting. Hangody et al (2001) reported that some patients had slight or moderate complaints with physical activity during the first postoperative year but there was no long-term donor-site pain in a series of 36 patients evaluated 2 to 7 years after AOT.

Filling defects with minced or particulated articular cartilage (autologous or allogeneic) is another single-stage procedure being investigated for cartilage repair. The Cartilage Autograft Implantation System (Johnson & Johnson) harvests cartilage and disperses chondrocytes on a scaffold in a single-stage treatment. The Reveille Cartilage Processor (Exactech Biologics) has a high-speed blade and sieve to cut autologous cartilage into small particles for implantation. BioCartilage (Arthrex) consists of a micronized allogeneic cartilage matrix that is intended to provide a scaffold for microfracture. DeNovo NT Graft (Natural Tissue Graft) is produced by ISTO Technologies and distributed by Zimmer. DeNovo NT consists of manually minced cartilage tissue pieces obtained from juvenile allograft donor joints. The tissue fragments are mixed intraoperatively with fibrin glue before implantation in the prepared lesion. It is thought that mincing the tissue helps both with cell migration from the extracellular matrix and with fixation.

A minimally processed osteochondral allograft (Chondrofix; Zimmer) is now available. Chondrofix is composed of decellularized hyaline cartilage and cancellous bone; it can be used “off the shelf” with precut cylinders (7-15 mm). Multiple cylinders may be used to fill a larger defect in a manner similar to AOT or mosaicplasty.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.





# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

ProChondrix (AlloSource) and Cartiform (Arthrex) are wafer-thin allografts where the bony portion of the allograft is reduced. The discs are laser etched or porated and contain hyaline cartilage with chondrocytes, growth factors, and extracellular matrix proteins. ProChondrix is available in dimensions from 7 to 20 mm and is stored fresh for a maximum of 28 days. Cartiform is cut to the desired size and shape and is stored frozen for a maximum of two years. The osteochondral discs are typically inserted after microfracture and secured in place with fibrin glue and/or sutures.

Autologous chondrocyte implantation is another method of cartilage repair involving the harvesting of normal chondrocytes from normal non-weight-bearing articular surfaces, which are then cultured and expanded in vitro and implanted back into the chondral defect. Autologous chondrocyte implantation techniques are discussed in medical policy 00006.

## **FDA or Other Governmental Regulatory Approval**

### **U.S. Food and Drug Administration (FDA)**

The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation, title 21, parts 1270 and 1271. Osteochondral grafts are included in these regulations.

DeNovo<sup>®†</sup> ET Live Chondral Engineered Tissue Graft (Neocartilage) is marketed by ISTO Technologies outside of the United States. The Food and Drug Administration approved ISTO's investigational new drug application for Neocartilage in 2006, which allowed ISTO to pursue phase 3 clinical trials of the product in human subjects. However, ISTO's clinical trial for Neocartilage was terminated due to poor enrollment as of August 31, 2017.

## **Rationale/Source**

Osteochondral grafts are used to repair full-thickness chondral defects involving a joint. In the case of osteochondral autografts, one or more small osteochondral plugs are harvested from non-weight-bearing sites, usually from the knee, and press fit into a prepared site in the lesion. Osteochondral allografts are typically used for larger lesions. Autologous or allogeneic minced cartilage, decellularized osteochondral allograft plugs, and reduced osteochondral allograft discs are also being evaluated as a treatment of articular cartilage lesions.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

The following conclusions are based on a review of the evidence, including but not limited to published evidence and clinical expert opinion, solicited via BCBSA's Clinical Input Process.

### **Knee Lesions**

For individuals who have full-thickness articular cartilage lesions of the knee who receive an osteochondral autograft, the evidence includes randomized controlled trials (RCTs), systematic reviews of RCTs, and longer term observational studies. The relevant outcomes are symptoms, functional outcomes, quality of life (QOL), and treatment-related morbidity. Several systematic reviews have evaluated osteochondral autografting for cartilage repair in the short- and mid-term. Compared with abrasion techniques (eg, microfracture, drilling), there is evidence that osteochondral autografting decreases failure rates and improves outcomes in patients with medium-size lesions (eg, 2-6 cm<sup>2</sup>) when measured at longer follow-up. This is believed to be due to the higher durability of hyaline cartilage compared with fibrocartilage from abrasion techniques. There appears to be a relatively narrow range of lesion size for which osteochondral autografting is most effective. The best results have also been observed with lesions on the femoral condyles, although treatment of lesions on the trochlea and patella may also improve outcomes. Correction of malalignment is important for the success of the procedure. The evidence suggests that osteochondral autografts may be considered an option for moderate-sized symptomatic full-thickness chondral lesions of the femoral condyle, trochlea, or patella. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have full-thickness articular cartilage lesions of the knee when autografting would be inadequate due to lesion size, location, or depth who receive a fresh osteochondral allograft, the evidence includes case series. The relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. Due to the lack of alternatives, this procedure may be considered a salvage operation in younger patients for full-thickness chondral defects of the knee caused by acute or repetitive trauma when other cartilage repair techniques (eg, microfracture, osteochondral autografting, autologous chondrocyte implantation) would be inadequate due to lesion size, location, or depth. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

### **Ankle Lesions**

For individuals who have primary full-thickness articular cartilage lesions of the ankle less than 1.5 cm<sup>2</sup> who receive an osteochondral autograft, the evidence includes observational studies and a

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

systematic review of these studies. The relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. A systematic review found similar improvements in outcomes following microfracture and autologous osteochondral transplantation (AOT). Given the success of marrow stimulation procedures for smaller lesions ( $<1.5 \text{ cm}^2$ ) and the increase in donor-site morbidity with graft harvest from the knee, current evidence does not support the use of AOT as a primary treatment for smaller articular cartilage lesions of the ankle. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have large (area  $>1.5 \text{ cm}^2$ ) or cystic (volume  $>3.0 \text{ cm}^3$ ) full-thickness articular cartilage lesions of the ankle who receive an osteochondral autograft, the evidence includes an RCT and several observational studies. The relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. An RCT in patients with large lesions found similar efficacy for AOT, marrow stimulation, and arthroplasty at two-year follow-up. Longer term results were not reported in the RCT. However, observational studies with longer term follow-up (four to five years) have shown favorable results for patients with large or cystic lesions receiving osteochondral autograft transplantation. Limitations of the published evidence preclude determining the effects of the technology on health outcomes. Evidence reported through clinical input supports that the use provides a clinically meaningful improvement in net health outcome and is consistent with generally accepted medical practice. Studies on the standard treatment for ankle lesions, marrow stimulation, have reported positive outcomes for patients with small lesions of the ankle ( $<1.5 \text{ cm}^2$ ) but have generally reported high failure rates for patients with large ( $>1.5 \text{ cm}^2$ ) lesions. Because the standard treatment has been shown to be less effective on larger lesions, there is support in the clinical community for osteochondral autografts in patients with large lesions of the ankle. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have osteochondral lesions of the ankle that have failed primary treatment who receive an osteochondral autograft, the evidence includes two nonrandomized comparative trials and several case series. The relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. The best evidence for revision AOT comes from a nonrandomized comparative study that found better outcomes with AOT than with repeat marrow stimulation. This finding is supported by case series that have indicated good-to-excellent results at mid-term and longer term follow-up with revision AOT. The published evidence supports a meaningful improvement in the net health outcome. Evidence reported through clinical input further supports that this use provides

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

a clinically meaningful improvement in net health outcome and is consistent with generally accepted medical practice. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have primary full-thickness articular cartilage lesions of the ankle less than 1.5 cm<sup>2</sup> who receive a fresh osteochondral allograft, there is little evidence. The relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. Because microfracture is effective as a primary treatment for lesions less than 1.5 cm<sup>2</sup> and AOT is effective as a revision procedure, use of allograft for small primary cartilage lesions has not been reported. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have large (area >1.5 cm<sup>2</sup>) or cystic (volume >3.0 cm<sup>3</sup>) cartilage lesions of the ankle when autografting would be inadequate who receive a fresh osteochondral allograft, the evidence includes a small number of patients in an RCT, case series, and a systematic review of case series. The relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. The majority of patients in the RCT were patients with revision osteochondral lesions, so conclusions about the few patients with primary lesions could not be made. The systematic review of case series reported improvements in ankle scores and decreases in pain scores, though 25% of patients needed additional surgery and 13% experienced either graft nonunion, resorption, or symptom persistence. Limitations of the published evidence preclude determining the effects of the technology on health outcomes. Evidence reported through clinical input supports that the use provides a clinically meaningful improvement in net health outcome and is consistent with generally accepted medical practice. For particularly large lesions, marrow stimulation techniques have been found to be ineffective and obtaining an adequate volume of autograft may cause significant morbidity. For these reasons, osteochondral allografts may be a considered option for large lesions of the ankle. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have revision osteochondral lesions of the ankle when autografting would be inadequate who receive a fresh osteochondral allograft, the evidence includes an RCT. The relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. Most of the patients in the RCT had failed a prior microfracture. The RCT found that outcomes were statistically similar with osteochondral allografts compared with autografts. However, failure rates due to nonunion were higher in patients in the allograft group compared with patients in the autograft group.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

Limitations of the published evidence preclude determining the effects of the technology on health outcomes. Evidence reported through clinical input supports that the use provides a clinically meaningful improvement in net health outcome and is consistent with generally accepted medical practice. For particularly large lesions, marrow stimulation techniques have been found to be ineffective and obtaining an adequate volume of autograft may cause significant morbidity. For these reasons, osteochondral allografts may be a considered option for revision of large lesions of the ankle. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

### **Elbow Lesions**

For individuals who have full-thickness articular cartilage lesions of the elbow who receive an osteochondral autograft, the evidence includes a meta-analysis of case series. The relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. Osteochondritis dissecans of the elbow typically occurs in patients who play baseball or do gymnastics. The literature on osteochondral autografts for advanced osteochondritis dissecans of the elbow consists of small case series, primarily from Europe and Asia, and a systematic review of case series. Although the meta-analysis suggested a benefit of osteochondral autografts compared with débridement or fixation, RCTs are needed to determine the effects of the procedure with greater certainty. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Shoulder Lesions**

For individuals who have full-thickness articular cartilage lesions of the shoulder who receive an osteochondral autograft, the evidence includes a case series. The relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. Evidence on osteochondral autografting for the shoulder is very limited. The evidence is insufficient to determine the effects of the technology on health outcomes.

### **Knee, Ankle, Elbow, or Shoulder Lesions**

For individuals who have full-thickness articular cartilage lesions of the knee, ankle, elbow, or shoulder who receive autologous or allogeneic minced or particulated articular cartilage, the evidence includes a small RCT and small case series. The relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. The evidence on autologous minced cartilage includes a small RCT. The evidence on allogeneic juvenile minced cartilage includes a few small case series. The case series have suggested an improvement in outcomes compared with

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.





# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

preoperative measures but there is also evidence of subchondral edema, nonhomogeneous surface, graft hypertrophy, and delamination. For articular cartilage lesions of the knee, further evidence, preferably from RCTs, is needed to evaluate the effect on health outcomes compared with other procedures. There are fewer options for articular cartilage lesions of the ankle. However, further study in a larger number of patients is needed to assess the short- and long-term effectiveness of this technology. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have full-thickness articular cartilage lesions of the knee, ankle, elbow, or shoulder who receive decellularized osteochondral allograft plugs or reduced osteochondral allograft discs, the evidence includes small case series. The relevant outcomes are symptoms, functional outcomes, QOL, and treatment-related morbidity. The case series on decellularized osteochondral allograft plugs reported delamination of the implants, and high failure rates. Evidence on reduced osteochondral allograft discs consists only of case reports and very small case series. The evidence is insufficient to determine the effects of the technology on health outcomes.

Clinical input obtained in 2017 supports that the following indications provide a clinically meaningful improvement in the net health outcome and are consistent with generally accepted medical practice.

- Use of osteochondral autograft for:
  - Primary treatment of large (area  $>1.5 \text{ cm}^2$ ) or cystic (volume  $>3.0 \text{ cm}^3$ ) osteochondral lesion of the talus.
  - Revision surgery after failed marrow stimulation for osteochondral lesion of the talus.
- Use of fresh osteochondral allograft for:
  - Primary treatment of large (area  $>1.5 \text{ cm}^2$ ) or cystic (volume  $>3.0 \text{ cm}^3$ ) osteochondral lesion of the talus when autografting would be inadequate due to lesion size, depth, or location.
  - Revision surgery for osteochondral lesions of the talus when autografting would be inadequate due to lesion size, depth, or location.

Thus, the above indications may be considered medically necessary considering the suggestive evidence and clinical input support.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.





# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

However, the clinical input does not support whether the following indication provides a clinically meaningful improvement in the net health outcome or is consistent with generally accepted medical practice.

- Use of osteochondral grafts in the elbow.

Thus, the above indication may be considered investigational.

### **Supplemental Information**

#### **Clinical Input From Physician Specialty Societies and Academic Medical Centers**

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

#### **2017 Input**

In response to requests, clinical input on osteochondral autografts improves for treating focal articular cartilage lesions in the ankle and elbow was received from 3 respondents, including 2 specialty society-level response and 1 physician from 1 health systems, while this policy was under review in 2017

#### **2011 Input**

In response to requests, input was received from 3 academic medical centers while this policy was under review in 2011. Input generally agreed with the stated criteria for osteochondral grafting, except the following: input was mixed on the requirement for an inadequate response to a prior surgical procedure, the size of the lesion, and the requirement for an absence of meniscal pathology. Input was also mixed on the investigational status of osteochondral grafts in other joints, including the patellar and talar joints, and for the use of autologous minced cartilage.

#### **2008 Input**

In response to requests, input was received from 1 physician specialty society and 3 academic medical centers while this policy was under review in 2008. All reviewers agreed that osteochondral autografts and allografts are considered reasonable for patients with full-thickness chondral defects who meet specific criteria.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

### Practice Guidelines and Position Statements

#### Ankle

##### **American Orthopaedic Foot and Ankle Society**

The American Orthopaedic Foot and Ankle Society (2018) issued a position statement on the use of osteochondral transplantation for the treatment of osteochondral lesions of the talus. In the statement, the Society "endorses the use of osteochondral autograft and allograft transplantation for the treatment of osteochondral lesion of the talus, especially large diameter lesions, cystic lesions, and those that have failed previous surgical treatment. AOFAS does not consider these procedures to be experimental in a patient population that has failed nonoperative management."

##### **International Consensus Group on Cartilage Repair of the Ankle**

The International Consensus Group on Cartilage Repair of the Ankle (2017) convened to review the best available evidence and develop consensus statements to guide management of patients needing cartilage repair of the ankle. The Consensus Group, consisting of 75 experts from 25 countries, acknowledged that evidence in the field of cartilage repair of the ankle is both low-quality and at low-levels. One topic addressed by the Consensus Group was the use of osteochondral allografts. Through a process based on the Delphi method of achieving consensus, the following recommendations were issued:

- Osteochondral allograft plugs may be preferred over autografts in the following conditions: lesions >1.5 cm; knee osteoarthritis; history of knee infection; patients expressing concern of donor site morbidity of the knee. (grade of evidence: prospective cohort study)
- The source of osteochondral allograft plugs for the ankle should come from the ankle, not the knee. (grade of evidence: basic science)
- There is an absence of clinical evidence and clinical experience for the use of decellularized osteochondral allograft plugs.
- The preferred type of allograft for the ankle is fresh, nonfrozen. (grade of evidence: basic science)

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

### **Elbow**

#### **American Academy of Orthopaedic Surgeons**

In 2010 guidelines, which remain available on the American Academy of Orthopaedic Surgeons website in 2018, on the diagnosis and treatment of osteochondritis dissecans, the Academy was unable to recommend for or against a specific cartilage repair technique in symptomatic skeletally immature or mature patients with an unsalvageable osteochondritis dissecans lesion.

A 2010 Academy review of articular cartilage restoration methods stated that “osteochondral autografting is generally used for smaller focal lesions of the femoral condyle no greater than 1.5 to 2 cm.”

### **Knee**

The National Institute for Health and Care Excellence (2018) issued a new guidance, mosaicplasty for symptomatic articular cartilage defects of the knee (IPG607). The guidance states that the evidence for safety and efficacy of mosaicplasty for knee cartilage defects is adequate to support the use of the procedure.

### **U.S. Preventive Services Task Force Recommendations**

Not applicable.

### **Medicare National Coverage**

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

### **Ongoing and Unpublished Clinical Trials**

Some currently unpublished trials that might influence this review are listed in Table 1.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

**Table 1. Summary of Key Trials**

NCT No.	Trial Name	Planned Enrollment	Completion Date
Ongoing			
NCT01347892 <sup>a</sup>	Post Market, Longitudinal Data Collection Study of Articular Cartilage Lesions in the Ankle Treated With DeNovo(R) NT	205	Sep 2019
NCT01329445 <sup>a</sup>	Post Market, Longitudinal Data Collection Study of DeNovo NT for Articular Cartilage Defects of the Knee	160	Dec 2021
NCT01670617 <sup>a</sup>	A Stratified, Post-Market Study of DeNovo NT for the Treatment of Femoral and Patellar Articular Cartilage Lesions of the Knee	90	Dec 2021

NCT: national clinical trial.

<sup>a</sup> Denotes industry-sponsored or cosponsored trial.

## **References**

1. Blue Cross and Blue Shield Association, Medical Policy Reference Manual, “Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions”, 7.01.78, May 2020.
2. AIM Specialty Health, Musculoskeletal Program Clinical Appropriateness Guidelines for Joint Surgery, “Treatment of Osteochondral Defects”, May 17, 2020.
3. Durur-Subasi I, Durur-Karakaya A, Yildirim OS. Osteochondral Lesions of Major Joints. *Eurasian J Med.* Jun 2015;47(2):138-144. PMID 26180500.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

4. Fortin, PP, Balazsy, JJ. Talus fractures: evaluation and treatment. *J Am Acad Orthop Surg*, 2001 Apr 3;9(2). PMID 11281635.
5. Mithoefer K, McAdams T, Williams RJ, et al. Clinical efficacy of the microfracture technique for articular cartilage repair in the knee: an evidence-based systematic analysis. *Am J Sports Med*. Oct 2009;37(10):2053-2063. PMID 19251676.
6. Solheim E, Hegna J, Inderhaug E, et al. Results at 10-14 years after microfracture treatment of articular cartilage defects in the knee. *Knee Surg Sports Traumatol Arthrosc*. May 2016;24(5):1587-1593. PMID 25416965.
7. Reddy S, Pedowitz DI, Parekh SG, et al. The morbidity associated with osteochondral harvest from asymptomatic knees for the treatment of osteochondral lesions of the talus. *Am J Sports Med*. Jan 2007;35(1):80-85. PMID 16957009.
8. Hangody L, Kish G, Modis L, et al. Mosaicplasty for the treatment of osteochondritis dissecans of the talus: two to seven year results in 36 patients. *Foot Ankle Int*. Jul 2001;22(7):552-558. PMID 11503979.
9. Gracitelli GC, Moraes VY, Franciozi CE, et al. Surgical interventions (microfracture, drilling, mosaicplasty, and allograft transplantation) for treating isolated cartilage defects of the knee in adults. *Cochrane Database Syst Rev*. Sep 03 2016;9:CD010675. PMID 27590275.
10. Magnussen RA, Dunn WR, Carey JL, et al. Treatment of focal articular cartilage defects in the knee: a systematic review. *Clin Orthop Relat Res*. Apr 2008;466(4):952-962. PMID 18196358.
11. Harris JD, Cavo M, Brophy R, et al. Biological knee reconstruction: a systematic review of combined meniscal allograft transplantation and cartilage repair or restoration. *Arthroscopy*. Oct 26 2011;27(3):409-418. PMID 21030203.
12. Hangody L, Kish G, Karpati Z, et al. Arthroscopic autogenous osteochondral mosaicplasty for the treatment of femoral condylar articular defects. A preliminary report. *Knee Surg Sports Traumatol Arthrosc*. Jan 1997;5(4):262-267. PMID 9430578.
13. Hangody L, Kish G, Karpati Z, et al. Mosaicplasty for the treatment of articular cartilage defects: application in clinical practice. *Orthopedics*. Jul 1998;21(7):751-756. PMID 9672912.
14. Hangody L, Vasarhelyi G, Hangody LR, et al. Autologous osteochondral grafting--technique and long-term results. *Injury*. Apr 2008;39(Suppl 1):S32-39. PMID 18313470.
15. Solheim E, Hegna J, Oyen J, et al. Osteochondral autografting (mosaicplasty) in articular cartilage defects in the knee: results at 5 to 9 years. *Knee*. Jan 2010;17(1):84-87. PMID 19666226.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

16. Solheim E, Hegna J, Oyen J, et al. Results at 10 to 14 years after osteochondral autografting (mosaicplasty) in articular cartilage defects in the knee. *Knee*. Aug 2013;20(4):287-290. PMID 23482060.
17. Marcacci M, Kon E, Delcogliano M, et al. Arthroscopic autologous osteochondral grafting for cartilage defects of the knee: prospective study results at a minimum 7-year follow-up. *Am J Sports Med*. Dec 2007;35(12):2014-2021. PMID 17724094.
18. Astur DC, Arliani GG, Binz M, et al. Autologous osteochondral transplantation for treating patellar chondral injuries: evaluation, treatment, and outcomes of a two-year follow-up study. *J Bone Joint Surg Am*. May 21 2014;96(10):816-823. PMID 24875022.
19. Nho SJ, Foo LF, Green DM, et al. Magnetic resonance imaging and clinical evaluation of patellar resurfacing with press-fit osteochondral autograft plugs. *Am J Sports Med*. Jun 2008;36(6):1101-1109. PMID 18337357.
20. De Caro F, Bisicchia S, Amendola A, et al. Large fresh osteochondral allografts of the knee: a systematic clinical and basic science review of the literature. *Arthroscopy*. Apr 2015;31(4):757-765. PMID 25660010.
21. Chui K, Jeys L, Snow M. Knee salvage procedures: The indications, techniques and outcomes of large osteochondral allografts. *World J Orthop*. Apr 18 2015;6(3):340-350. PMID 25893177.
22. Nielsen ES, McCauley JC, Pulido PA, et al. Return to sport and recreational activity after osteochondral allograft transplantation in the knee. *Am J Sports Med*. Jun 2017;45(7):1608-1614. PMID 28375642.
23. Gracitelli GC, Meric G, Briggs DT, et al. Fresh osteochondral allografts in the knee: comparison of primary transplantation versus transplantation after failure of previous subchondral marrow stimulation. *Am J Sports Med*. Apr 2015;43(4):885-891. PMID 25817190.
24. Zengerink M, Struijs PA, Tol JL, et al. Treatment of osteochondral lesions of the talus: a systematic review. *Knee Surg Sports Traumatol Arthrosc*. Feb 2010;18(2):238-246. PMID 19859695.
25. Gobbi A, Francisco RA, Lubowitz JH, et al. Osteochondral lesions of the talus: randomized controlled trial comparing chondroplasty, microfracture, and osteochondral autograft transplantation. *Arthroscopy*. Oct 2006;22(10):1085-1092. PMID 17027406.
26. Choi WJ, Park KK, Kim BS, et al. Osteochondral lesion of the talus: is there a critical defect size for poor outcome? *Am J Sports Med*. Oct 2009;37(10):1974-1980. PMID 19654429.
27. Chuckpaiwong B, Berkson EM, Theodore GH. Microfracture for osteochondral lesions of the ankle: outcome analysis and outcome predictors of 105 cases. *Arthroscopy*. Jan 2008;24(1):106-112. PMID 18182210.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.





# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

28. Cuttica DJ, Smith WB, Hyer CF, et al. Osteochondral lesions of the talus: predictors of clinical outcome. *Foot Ankle Int.* Nov 2011;32(11):1045-1051. PMID 22338953.
29. Ramponi L, Yasui Y, Murawski CD, et al. Lesion size is a predictor of clinical outcomes after bone marrow stimulation for osteochondral lesions of the talus. *Am J Sports Med.* Jun 2017;45(7):1698-1705. PMID 27852595.
30. Haleem AM, Ross KA, Smyth NA, et al. Double-plug autologous osteochondral transplantation shows equal functional outcomes compared with single-plug procedures in lesions of the talar dome: a minimum 5-year clinical follow-up. *Am J Sports Med.* Aug 2014;42(8):1888-1895. PMID 24948585.
31. Shimozone, YY, Hurley, EE, Nguyen, JJ, Deyer, TT, Kennedy, JJ. Allograft Compared with Autograft in Osteochondral Transplantation for the Treatment of Osteochondral Lesions of the Talus. *J Bone Joint Surg Am.* 2018 Nov 7;100(21). PMID 30399078.
32. Yoon HS, Park YJ, Lee M, et al. Osteochondral autologous transplantation is superior to repeat arthroscopy for the treatment of osteochondral lesions of the talus after failed primary arthroscopic treatment. *Am J Sports Med.* Aug 2014;42(8):1896-1903. PMID 24907287.
33. Imhoff AB, Paul J, Ottinger B, et al. Osteochondral transplantation of the talus: long-term clinical and magnetic resonance imaging evaluation. *Am J Sports Med.* Jul 2011;39(7):1487-1493. PMID 21372316.
34. Kreuz PC, Steinwachs M, Erggelet C, et al. Mosaicplasty with autogenous talar autograft for osteochondral lesions of the talus after failed primary arthroscopic management: a prospective study with a 4-year follow-up. *Am J Sports Med.* Jan 2006;34(1):55-63. PMID 16157849.
35. Georgiannos D, Bisbinas I, Badeskas A. Osteochondral transplantation of autologous graft for the treatment of osteochondral lesions of talus: 5- to 7-year follow-up. *Knee Surg Sports Traumatol Arthrosc.* Dec 2016;24(12):3722-3729. PMID 25326766.
36. Diniz, PP, Pacheco, JJ, Flora, MM, Quintero, DD, Stufkens, SS, Kerkhoffs, GG, Batista, JJ, Karlsson, JJ, Pereira, HH. Clinical applications of allografts in foot and ankle surgery. *Knee Surg Sports Traumatol Arthrosc.* 2019 Feb 6. PMID 30721345.
37. van Dijk CN. Editorial commentary: Bulk osteochondral talar grafts compromise future arthrodesis or prosthesis. *Arthroscopy.* Jan 2017;33(1):223-224. PMID 28003071.
38. VanTijenderen RJ, Dunn JC, Kusnezov N, et al. Osteochondral allograft transfer for treatment of osteochondral lesions of the talus: a systematic review. *Arthroscopy.* Jan 2017;33(1):217-222. PMID 27546173.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

39. Ahmad J, Jones K. Comparison of osteochondral autografts and allografts for treatment of recurrent or large talar osteochondral lesions. *Foot Ankle Int.* Jan 2016;37(1):40-50. PMID 26333683.
40. Gaul, FF, Tírico, LL, McCauley, JJ, Pulido, PP, Bugbee, WW. Osteochondral Allograft Transplantation for Osteochondral Lesions of the Talus: Midterm Follow-up. *Foot Ankle Int.* 2018 Nov 2;40(2). PMID 30383977.
41. Westermann RW, Hancock KJ, Buckwalter JA, et al. Return to sport after operative management of osteochondritis dissecans of the capitellum: a systematic review and meta-analysis. *Orthop J Sports Med.* Jun 2016;4(6):2325967116654651. PMID 27482526.
42. Kirsch, JJ, Thomas, JJ, Khan, MM, Townsend, WW, Lawton, JJ, Bedi, AA. Return to Play After Osteochondral Autograft Transplantation of the Capitellum: A Systematic Review. *Arthroscopy.* 2017 Apr 18;33(7). PMID 28413129.
43. Sato, KK, Iwamoto, TT, Matsumura, NN, Suzuki, TT, Nishiwaki, YY, Oka, YY, Nakamura, TT. Costal Osteochondral Autograft for Advanced Osteochondritis Dissecans of the Humeral Capitellum in Adolescent and Young Adult Athletes: Clinical Outcomes with a Mean Follow-up of 4.8 Years. *J Bone Joint Surg Am.* 2018 Jun 6;100(11). PMID 29870440.
44. Bexkens R, Ogink PT, Doornberg JN, et al. Donor-site morbidity after osteochondral autologous transplantation for osteochondritis dissecans of the capitellum: a systematic review and meta-analysis. *Knee Surg Sports Traumatol Arthrosc.* Jul 2017;25(7):2237-2246. PMID 28391550.
45. Kircher J, Patzer T, Magosch P, et al. Osteochondral autologous transplantation for the treatment of full-thickness cartilage defects of the shoulder: results at nine years. *J Bone Joint Surg Br.* Apr 2009;91(4):499-503. PMID 19336811.
46. Cole BJ, Farr J, Winalski CS, et al. Outcomes after a single-stage procedure for cell-based cartilage repair: a prospective clinical safety trial with 2-year follow-up. *Am J Sports Med.* Jun 2011;39(6):1170-1179. PMID 21460066.
47. Farr J, Tabet SK, Margerrison E, et al. Clinical, radiographic, and histological outcomes after cartilage repair with particulated juvenile articular cartilage: a 2-year prospective study. *Am J Sports Med.* Apr 9 2014;42(6):1417-1425. PMID 24718790.
48. Tompkins M, Hamann JC, Diduch DR, et al. Preliminary results of a novel single-stage cartilage restoration technique: particulated juvenile articular cartilage allograft for chondral defects of the patella. *Arthroscopy.* Oct 2013;29(10):1661-1670. PMID 23876608.
49. Saltzman BM, Lin J, Lee S. Particulated juvenile articular cartilage allograft transplantation for osteochondral talar lesions. *Cartilage.* Jan 2017;8(1):61-72. PMID 27994721.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

50. Bleazey S, Brigido SA. Reconstruction of complex osteochondral lesions of the talus with cylindrical sponge allograft and particulate juvenile cartilage graft: provisional results with a short-term follow-up. *Foot Ankle Spec.* Oct 2012;5(5):300-305. PMID 22935411.
51. Coetzee JC, Giza E, Schon LC, et al. Treatment of osteochondral lesions of the talus with particulated juvenile cartilage. *Foot Ankle Int.* Sep 2013;34(9):1205-1211. PMID 23576118.
52. Dekker, TT, Steele, JJ, Federer, AA, Easley, MM, Hamid, KK, Adams, SS. Efficacy of Particulated Juvenile Cartilage Allograft Transplantation for Osteochondral Lesions of the Talus. *Foot Ankle Int.* 2017 Dec 22;39(3). PMID 29262723.
53. DeSandis, BB, Haleem, AA, Sofka, CC, O'Malley, MM, Drakos, MM. Arthroscopic Treatment of Osteochondral Lesions of the Talus Using Juvenile Articular Cartilage Allograft and Autologous Bone Marrow Aspirate Concentration. *J Foot Ankle Surg.* 2018 Jan 7;57(2). PMID 29305041.
54. Farr J, Gracitelli GC, Shah N, et al. High failure rate of a decellularized osteochondral allograft for the treatment of cartilage lesions. *Am J Sports Med.* Aug 2016;44(8):2015-2022. PMID 27179056.
55. Johnson CC, Johnson DJ, Garcia GH, et al. High short-term failure rate associated with decellularized osteochondral allograft for treatment of knee cartilage lesions. *Arthroscopy.* Dec 2017;33(12):2219-2227. PMID 28967543.
56. American Orthopaedic Foot and Ankle Society. Position Statement: The Use of Osteochondral Transplantation for the Treatment of Osteochondral Lesions of the Talus. [https://www.aofas.org/docs/default-source/research-and-policy/osteochondral-lesions-position-statement.pdf?sfvrsn=95e8c93b\\_2](https://www.aofas.org/docs/default-source/research-and-policy/osteochondral-lesions-position-statement.pdf?sfvrsn=95e8c93b_2).
57. Smyth, NN, Murawski, CC, Adams, SS, Berlet, GG, Buda, RR, Labib, SS, Nunley, JJ, Raikin, SS, Ackermann, JJ, Andrews, CC, Anghong, CC, Batista, JJ, Baur, OO, Bayer, SS, Becher, CC, Boakye, LL, Brown, AA, Calder, JJ, Canata, GG, Carreira, DD, Clanton, TT, Dahmen, JJ, D'Hooghe, PP, DiGiovanni, CC, Dombrowski, MM, Drakos, MM, Ferkel, RR, Ferrao, PP, Fortier, LL, Glazebrook, MM, Giza, EE, Gomaa, MM, Görtz, SS, Haleem, AA, Hamid, KK, Hangody, LL, Hannon, CC, Haverkamp, DD, Hertel, JJ, Hintermann, BB, Hogan, MM, Hunt, KK, Hurley, EE, Karlsson, JJ, Kearns, SS, Kennedy, JJ, Kerkhoffs, GG, Kim, HH, Kong, SS, Lambers, KK, Lee, JJ, Lee, KK, Ling, JJ, Longo, UU, Marangon, AA, McCollum, GG, Mitchell, AA, Mittwede, PP, Nehrer, SS, Niemeyer, PP, O'Malley, MM, Osei-Hwedieh, DD, Paul, JJ, Pearce, CC, Pereira, HH, Popchak, AA, Prado, MM, Reilingh, MM, Rothrauff, BB, Schon, LL, Shimozone, YY, Simpson, HH, Sofka, CC, Spennacchio, PP, Stone, JJ, Sullivan, MM, Takao, MM, Tanaka, YY, Thordarson, DD, Tuan, RR, Valderrabano, VV, van Bergen, CC, van Dijk,

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

- CC, van Dijk, PP, Vannini, FF, Vaseenon, TT, Walther, MM, Wiewiorski, MM, Xu, XX, Yasui, YY, Yinghui, HH, Yoshimura, II, Younger, AA, Zhang, ZZ. Osteochondral Allograft: Proceedings of the International Consensus Meeting on Cartilage Repair of the Ankle. *Foot Ankle Int*, 2018 Sep 15;39(1\_suppl). PMID 30215308.
58. American Academy of Orthopaedic Surgeons Diagnosis and Treatment of Osteochondritis Dissecans Work Group. The diagnosis and treatment of osteochondritis dissecans: Guideline and evidence report. 2010, December 4; [http://www.aaos.org/research/guidelines/OCD\\_guideline.pdf](http://www.aaos.org/research/guidelines/OCD_guideline.pdf).
59. Chambers HG, Shea KG, Anderson AF, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: the diagnosis and treatment of osteochondritis dissecans. *J Bone Joint Surg Am*. Jul 18 2012;94(14):1322-1324. PMID 22810404.
60. Trice ME, Bugbee WD, Greenwald AS, et al. Articular cartilage restoration: A review of currently available methods. 2010; [http://www.aaos.org/cc\\_files/aaosorg/research/committee/biologic/bi\\_se\\_2010.pdf](http://www.aaos.org/cc_files/aaosorg/research/committee/biologic/bi_se_2010.pdf).
61. National Institute for Health and Care Excellence. Mosaicplasty for symptomatic articular defects of the knee [IPG607]. <https://www.nice.org.uk/guidance/ipg607>.

### **Policy History**

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

- 07/18/2002 Medical Policy Committee review
- 08/26/2002 Managed Care Advisory Council approval
- 08/31/2004 Medical Director review
- 09/21/2004 Medical Policy Committee review. Format revision. No substance change to policy.
- 09/27/2004 Managed Care Advisory Council approval
- 12/07/2004 Medical Director review
- 12/14/2004 Medical Policy Committee review. Coverage eligibility criteria revisions. Policy expanded to address osteochondral allografts as well as Osteochondral autografts.
- 01/31/2005 Managed Care Advisory Council approval
- 02/01/2006 Medical Director review
- 02/15/2006 Medical Policy Committee review
- 02/23/2006 Quality Care Advisory Council approval

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

07/07/2006	Format revision, including addition of FDA and or other governmental regulatory approval and rationale/source. Coverage eligibility unchanged.
04/04/2007	Medical Director review
04/18/2007	Medical Policy Committee approval. No change to coverage eligibility.
04/02/2008	Medical Director review
04/16/2008	Medical Policy Committee approval. No change to coverage eligibility.
04/02/2009	Medical Director review
04/15/2009	Medical Policy Committee approval. No change to coverage eligibility.
04/08/2010	Medical Director review
04/21/2010	Medical Policy Committee approval. No change to coverage eligibility.
04/07/2011	Medical Policy Committee approval
04/13/2011	Medical Policy Implementation Committee approval. No change to coverage eligibility.
04/12/2012	Medical Policy Committee review
04/25/2012	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
04/04/2013	Medical Policy Committee review
04/24/2013	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
04/03/2014	Medical Policy Committee review
04/23/2014	Medical Policy Implementation Committee approval. Investigational statements added on autologous and allogeneic minced cartilage.
09/03/2015	Medical Policy Committee review
09/23/2015	Medical Policy Implementation Committee approval. Added defect of patella area to eligibility criteria for osteochondral autografting. Title change.
11/03/2016	Medical Policy Committee review
11/16/2016	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/01/2017	Coding update: Removing ICD-9 Diagnosis Codes
02/02/2017	Medical Policy Committee review
02/15/2017	Medical Policy Implementation Committee approval. Patient age limit in criteria changed from 50 to 55. Investigational statements added for decellularized osteochondral allograft plugs (eg, Chondrofix) and reduced osteochondral allograft discs (eg, ProChondrix, Cartiform).

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.





# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

02/01/2018 Medical Policy Committee review

02/21/2018 Medical Policy Implementation Committee approval.

For autograft or autologous mosaicplasty of the knee, criteria loosened to align with AIM Guidelines as follows:

- Persistent symptoms of disabling localized knee pain for at least three (3) months, which has failed to respond to conservative treatment.

Added a “*Note*” regarding corrective procedures following allograft of the knee.

Added autograft and allograft of the talus to be eligible for coverage with criteria to align with BCBSA.

For allograft of the knee, criteria changes made to align with AIM Guidelines as follows :

- Size of the cartilage defect is greater than or equal to 2 cm<sup>2</sup> total area, as documented by MRI or arthroscopy;
- Skeletal maturity as documented by closure of growth plates;
- Persistent symptoms of disabling localized knee pain for at least three (3) months, which has failed to respond to conservative treatment;
- Normal joint space present, without evidence of inflammation or degenerative changes.

Exclusion criteria revised and exclusion subtitle is specified for autografts and allografts of the knee.

Removed “the ankle (talus)” from the investigational statement for the use of osteochondral autograft/mosaicplasty and osteochondral allograft transplantation for joints other than the knee to expand coverage eligibility.

02/07/2019 Medical Policy Committee review

02/20/2019 Medical Policy Implementation Committee approval. Added “or particulated” to the investigational policy statements on minced cartilage. Added a Policy Guidelines section addressing conservative management from AIM Guidelines.

02/06/2020 Medical Policy Committee review

02/12/2020 Medical Policy Implementation Committee approval. Revised eligible for coverage criteria for autograft or autologous mosaicplasty of the knee and allograft of the knee to include conservative treatment to be tried and failed for a minimum 6 weeks as follows: “persistent symptoms of disabling localized knee pain for at least three (3) months, which has failed to respond to conservative treatment tried for a

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.





# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

minimum of 6 weeks". Updated conservative management information in the Policy Guidelines to track AIM Guidelines.

09/10/2020 Coding update

02/04/2021 Medical Policy Committee review

02/10/2021 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.

Next Scheduled Review Date: 02/2022

### **Coding**

*The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)‡, copyright 2020 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.*

*The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.*

CPT is a registered trademark of the American Medical Association.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	20932, 27415, 27416, 28446, 29866, 29867
HCPCS	No codes
ICD-10 Diagnosis	M12.561-M12.569, M17.0-M17.2, M17.30-M17.9, M23.50, M23.8X9, M24.361-M24.369, M25.161-M25.169, M25.261-M25.269, M25.361-M25.369, M25.861-M25.869, M85.9, M89.9, M93.20-M93.29, M94.9, S86.001A-S86.009A, S86.091A-S86.099A, S86.101A-S86.109A, S86.191A-S86.199A, S86.201A-S86.209A, S86.291A-S86.299A, S86.301A-S86.309A, S86.391A-S86.399A, S86.801A-S86.809A, S86.891A-S86.899A, S86.901A-S86.909A, S86.991A-S86.999A, S89.80XA-S89.82XA, S89.90XA-S89.92XA, S96.001A-S96.009A, S96.091A-S96.099A, S96.101A-S96.109A, S96.191A-S86.199A, S96.201A-S96.209A, S96.291A-S96.299A, S96.801A-S96.809A, S96.891A-S96.899A, S96.901A-S96.909A, S96.991A-S96.999A, S99.811A-S99.819A, S99.821A-S99.829A, S99.911A-S99.919A, S99.921A-S99.929A Added codes eff 10/01/2020: M24.19, M24.29, M24.39, M24.49, M24.59, M24.69, M24.89

\*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



# Louisiana

## Autografts and Allografts in the Treatment of Focal Articular Cartilage Lesions

Policy # 00091

Original Effective Date: 08/26/2002

Current Effective Date: 05/01/2021

diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

**\*\*Medically Necessary (or “Medical Necessity”)** - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

**NOTICE:** If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

**NOTICE:** Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.